Scientists are using gene editing to create the perfect tomato for your salad – Quartz
Quartz |
Scientists are using gene editing to create the perfect tomato for your salad
Quartz In a study published in the journal Cell on May 18, geneticist Zachary Lippman of Cold Spring Harbor Laboratory explains his research team’s efforts to fix mutated tomatoes using CRISPR gene editing technology. By identifying the genes associated with … |
|
French Biotech Enters New Agreement to Advance its IBD Immunotherapy
Labiotech.eu (blog) “We are pleased to advance our collaboration with Selexis with the initiation of a key step for our immunotherapy OSE-127 towards the clinical stage and its development in ulcerative colitis,” said Dominique Costantini, CEO of OSE Immunotherapeutics. |
|
Success of stem cell therapy for diabetes depends on pre-transplant immune condition
Medical Xpress An innovative method for treating type 1 diabetes based on the transplantation of hematopoietic stem cells taken from the patient’s own bone marrow began undergoing testing in Brazil 13 years ago. The results were highly variable. While some of the … |
|
Success of stem cell therapy for diabetes depends on pre-transplant immune condition
Medical Xpress An innovative method for treating type 1 diabetes based on the transplantation of hematopoietic stem cells taken from the patient’s own bone marrow began undergoing testing in Brazil 13 years ago. The results were highly variable. While some of the … |
|
Programming T cells in situ
Nature.com Smith et al. describe a method of programming T cells in situ using DNA-carrying nanoparticles. Nanoparticles were targeted to T cells and loaded with DNA encoding the leukaemia-specific CD19−4-1BB−CD3ζ (194-1BBz) CAR; this DNA sequence was … |
Technology Networks |
‘Signal’ Crucial to Stem Cell Function in Hair Follicles Identified
Technology Networks “This is the first study to identify the signals that influence hair follicle dermal stem cell function in your skin,” says Biernaskie, an associate professor in comparative biology and experimental medicine at the University of Calgary’s Faculty of … |
Cancer Network |
FDA Approves Immunotherapy for MSI-High or MMR-Deficient Tumors
Cancer Network The US Food and Drug Administration (FDA) has granted accelerated approval to pembrolizumab (Keytruda) for pediatric and adult patients with microsatellite instability (MSI)-high or mismatch repair (MMR)-deficient solid tumors. The indication is for … Urothelial Carcinoma Experts Optimistic for Durvalumab/Tremelimumab ComboTargeted Oncology FDA clears Merck’s Keytruda based on cancer genetics, not locationWHTC FDA Landmark Nod: Cancer Drug To Match Tumor Genes, Not Tissue TypeXconomy MedCity News all 40 news articles » |
|
BRIEF-Lysogene selects Brammer Bio to produce GM1 gangliosidosis gene therapy product
Reuters Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world’s largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news … |